New combo therapy aims to shrink untreatable liver tumors

NCT ID NCT07334483

Recruiting now Disease control Sponsor: GrandPharma (China) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated Apr 28, 2026 · Updated 17 times

Summary

This study is for people with liver cancer that cannot be surgically removed or treated with ablation. It compares a standard treatment called cTACE with a newer approach using tiny radioactive beads (yttrium-90) alone or combined with immunotherapy drugs (camrelizumab and/or apatinib). The goal is to see which treatment shrinks tumors best and is safe. About 120 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nanjing Tianyinshan Hospital
NOT_YET_RECRUITING

Nanjin, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HCC